Characterisation of the new EpCAM-specific antibody HO-3: implications for trifunctional antibody immunotherapy of cancer
about
The epithelial cell adhesion molecule EpCAM is required for epithelial morphogenesis and integrity during zebrafish epiboly and skin developmentThe trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trialTargeted immune therapy of ovarian cancerMechanisms of action of therapeutic antibodies for cancerInitial activation of EpCAM cleavage via cell-to-cell contact.Pharmacokinetics, immunogenicity and bioactivity of the therapeutic antibody catumaxomab intraperitoneally administered to cancer patientsFirst patient treated with a re-challenge of catumaxomab in recurrent malignant ascites: a case report.Intra- and postoperative catumaxomab in patients with epithelial ovarian cancer: safety and two-year efficacy results from a multicentre, single-arm, phase II studyA phase 1b study of humanized KS-interleukin-2 (huKS-IL2) immunocytokine with cyclophosphamide in patients with EpCAM-positive advanced solid tumors.Structural and functional characterization of the trifunctional antibody catumaxomabCatumaxomab--trifunctional anti-EpCAM antibody used to treat malignant ascites.Novel monoclonal antibodies for cancer treatment: the trifunctional antibody catumaxomab (removab).Immunity and immune suppression in human ovarian cancer.Humoral response to catumaxomab correlates with clinical outcome: results of the pivotal phase II/III study in patients with malignant ascitesAssessment of molecular interactions through magnetic relaxation.An anti-EpCAM antibody EpAb2-6 for the treatment of colon cancer.Outpatient Intraperitoneal Catumaxomab Therapy for Malignant Ascites Related to Advanced Gynecologic Neoplasms.Generation and characterization of rendomab-B1, a monoclonal antibody displaying potent and specific antagonism of the human endothelin B receptorCharacterization of the first-in-class T-cell-engaging bispecific single-chain antibody for targeted immunotherapy of solid tumors expressing the oncofetal protein claudin 6Epithelial cell-adhesion molecule-directed trifunctional antibody immunotherapy for symptom management of advanced ovarian cancer.Rendomab B4, a monoclonal antibody that discriminates the human endothelin B receptor of melanoma cells and inhibits their migration.Bispecific antibodies for cancer therapy.Review of catumaxomab in the treatment of malignant ascitesMonoclonal antibodies and antibody fragments: state of the art and future perspectives in the treatment of non-haematological tumors.Catumaxomab: in malignant ascites.Extraperitoneal response to intraperitoneal immunotherapy with catumaxomab in a patient with cutaneous lymphangiosis carcinomatosa from ovarian cancer: a case report and review of the literature.Monoclonal antibodies therapies for ovarian cancer.Monoclonal antibodies in gastrointestinal cancers.Development and prospects for bispecific antibody-based therapeutics in cancer and other applications.Drug development for intraperitoneal chemotherapy against peritoneal carcinomatosis from gastrointestinal cancer.Cell surface markers of cancer stem cells: diagnostic macromolecules and targets for drug delivery.Intraperitoneal immunotherapy: historical perspectives and modern therapy.Pancreas Adenocarcinoma: Ascites, Clinical Manifestations, and Management Implications.CD133 induces tumour-initiating properties in HEK293 cells.Trifunctional antibodies induce efficient antitumour activity with immune cells from head and neck squamous cell carcinoma patients after radio-chemotherapy treatment.Use of tissue cross-reactivity studies in the development of antibody-based biopharmaceuticals: history, experience, methodology, and future directions.Catumaxomab with and without prednisolone premedication for the treatment of malignant ascites due to epithelial cancer: results of the randomised phase IIIb CASIMAS study.Recent advances of bispecific antibodies in solid tumors.Ganglioside GD2-specific trifunctional surrogate antibody Surek demonstrates therapeutic activity in a mouse melanoma model.Re-challenge with catumaxomab in patients with malignant ascites: results from the SECIMAS study.
P2860
Q21563339-28AFDF1D-487A-401F-BD51-C8FACB40BD72Q24629295-0A88ED6A-A402-4DFA-AAB3-A38CD5164072Q28082828-D4797D3B-ABAD-4DCE-B098-3F7A4BF44C39Q28385366-3E966936-8633-46AF-934E-56746AC11525Q30898801-2319FF07-656C-4E65-84FF-0DABC2C8BA98Q33885497-AE39BC0F-4502-47A5-825A-1C34080E8EDAQ34182845-BD546F09-DDAA-4ED7-B76D-7F6A69F7D277Q34354529-8D12BA9E-947E-493C-9F0C-4991FF70F8C3Q34548847-81898838-2659-40A5-AE85-EF7CE846983CQ34619043-A962DF3C-EE7C-445C-93B8-22AC08E08F6FQ34621433-8A2E0EF8-BA56-443A-9F06-B61FFD87CA4FQ35057971-C5DFD381-D8E0-4AB6-A2A8-27A1570B55D3Q35138135-11FB207D-1F42-43B4-90A0-7A70884A37C3Q36153347-CF5F2859-D2CF-4D1D-A831-1BF7319A4E30Q36290548-B992F357-2C51-480A-81DC-4BD39C07F63DQ36413078-E5E60613-28BE-48FD-A0CF-B03264BC17C5Q36478769-4BE2AFF1-32F4-46C6-A4CC-CAE5224850B4Q36588721-AC718B7A-3EE3-4928-B970-2C43C3115B98Q36821083-99C7806F-5923-4D4B-AD5D-4C77C1EBC61DQ37225693-2F683F66-0079-47C5-B4F6-A1012F60C6B9Q37327310-8A1BB893-90E3-4D5A-8093-36A142E5AEF7Q37773263-D1E0403C-DDE5-49F5-A374-53960067B27BQ37824256-EAE9C65A-58FB-4F36-9986-FFB4A9CB96A9Q37887819-3D7CF4EC-D84C-4FFB-A196-DC884E7F2661Q38016957-71373135-6844-42D2-9DCD-682973C162A3Q38022538-99B9515E-4724-4080-B731-E03941907774Q38078400-FDCC77F6-1FE0-47AA-AAB2-B5450E62DC53Q38084684-D9C88AD0-B60D-48FE-A48E-5ECFE41E62CBQ38090680-11A84B02-5CDB-4813-A700-C59C53DCE6FCQ38183786-1A00AB2C-60ED-45B9-8B7D-A193C7ECD9EDQ38383345-F82F4D43-CE7D-46A2-B124-566B95720D14Q39005211-F35EBA67-0B2D-401A-BA1D-7CDAFC172E35Q39171689-EFA70619-E735-450E-9C1E-4B07A698F5E5Q39245279-2220AB82-A1D9-4FE2-83A7-72D17D6C2FA8Q39435767-375EE38B-4354-473D-9FDA-5F4437E92C99Q39647460-91D16C48-775D-4167-AC94-BC17BF42989BQ40202331-971417E1-1DD4-4B25-9DC9-C8EE192F938DQ41696278-D9AB6A89-88B9-453F-83EF-89FF1A0A9560Q42053371-545A65DB-D10F-4165-A7E5-ABF7B75D8F3BQ43728324-60CD5B46-FE4B-43BD-803F-8A07A548BFA9
P2860
Characterisation of the new EpCAM-specific antibody HO-3: implications for trifunctional antibody immunotherapy of cancer
description
2007 nî lūn-bûn
@nan
2007 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Characterisation of the new Ep ...... tibody immunotherapy of cancer
@ast
Characterisation of the new Ep ...... tibody immunotherapy of cancer
@en
Characterisation of the new Ep ...... tibody immunotherapy of cancer
@nl
type
label
Characterisation of the new Ep ...... tibody immunotherapy of cancer
@ast
Characterisation of the new Ep ...... tibody immunotherapy of cancer
@en
Characterisation of the new Ep ...... tibody immunotherapy of cancer
@nl
prefLabel
Characterisation of the new Ep ...... tibody immunotherapy of cancer
@ast
Characterisation of the new Ep ...... tibody immunotherapy of cancer
@en
Characterisation of the new Ep ...... tibody immunotherapy of cancer
@nl
P2093
P2860
P356
P1476
Characterisation of the new Ep ...... tibody immunotherapy of cancer
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.BJC.6603881
P407
P577
2007-07-10T00:00:00Z
P5875
P6179
1044576898